antioxidant/stroke

FIELD OF INVENTION This invention relates to treatment of CNS damage. Specifically, the invention provides for upregulating anti-oxidant proteins in neurons to effect treatment, and prevent neuronal damage. BACKGROUND OF THE INVENTION Stroke is the third leading cause of death in the United States,

FIELD OF THE INVENTION This disclosure is in the fields of pharmacology and medicine. More particularly, this disclosure relates to the treatment of neurodegenerative brain pathologies. BACKGROUND Age-related brain pathologies caused by neurodegeneration (ND), such as Alzheimer's disease (AD) and

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to methods for preconditioning and/or providing neuroprotection to the animal central nervous system against ischemia, neurodegeneration, trauma and metal poisoning, including associated cognitive, behavioral and

BACKGROUND OF THE INVENTION Field of the Invention The present invention is directed to methods for preconditioning and/or providing neuroprotection to the animal central nervous system against ischemia, neurodegeneration, trauma and metal poisoning, including associated cognitive, behavioral and

BACKGROUND OF THE INVENTION Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl-D-cysteine as a cytoprotective agent to prevent reperfusion injury of the blood-brain barrier that may contribute to hemorrhagic transformation due to thrombolysis following an

CROSS REFERENCE TO RELATED APPLICATIONS This is a National Stage of Application No. PCT/KR2015/012845 filed Nov. 27, 2015, claiming priority based on Korean Patent Application No. 10-2014-0167876 filed Nov. 27, 2014, the contents of all of which are incorporated herein by reference in their

FIELD OF THE INVENTION This invention relates to novel synthetic organic antioxidants of small molecules, their rational design, their proposed chemical preparation, and their potential uses in application to treatment and/or prevention of major diseases associated with oxidative stress. BACKGROUND

RELATED APPLICATIONS This application is a 35 U.S.C. .sctn. 371 national stage filing of International Application No. PCT/ES2014/070421, filed on May 22, 2014, which claims priority to Spanish Patent Application No. P201330738, filed on May 22, 2013. The entire contents of each of the foregoing

FIELD OF THE INVENTION The present invention relates to a new medical use of, and method of treatment using, the hydroxycarbazole compounds of Formula I, as oxygen radical scavengers, or antioxidants, for protection of vital organs, particularly the cardiovascular system including the heart, from

This application claims priority to provisional application 60-012633, filed Mar. 1, 1996. BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the use of metabolites of propranolol which is a commercially available pharmaceutical compound used in the treatment of

This patent application claims a benefit of priority from Korean Patent Application No. 2001/73301 filed Nov. 23, 2001, Korean Patent Application No. 2001/73307 filed Nov. 23, 2001 and Korean Patent Application No. 2002/42579 filed Jul. 19, 2002, the contents of each of which is incorporated herein

TECHNICAL FIELD The invention relates to the milk protein A2 beta-casein and improving the antioxidant capacity in an animal by increasing the levels of glutathione in the body of the animal. In particular, the invention relates to milk and milk derived food products. The applicant has found that

FIELD OF THE INVENTION The present invention relates to a composition of lubricating oil for two stroke gasoline engine and process for the preparation thereof. This invention particularly relates to composition of lubricating oil for two stroke gasoline engine that mainly contains alkyl benzenes.

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl antioxidants, particularly .gamma.-glutamyl -cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the use of .gamma.-glutamyl antioxidants, particularly .gamma.-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier